16 results on '"Richman, Sandra"'
Search Results
2. Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
3. Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
4. A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
5. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
6. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1
7. Pharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: Results from two Phase 1 clinical studies
8. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
9. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
10. Anti-JC Virus (JCV) Antibody Index Differentiates Risk of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-Treated Multiple Sclerosis (MS) Patients with No Prior Immunosuppressant (IS) Use: An Updated Analysis (P4.031)
11. Outcome and survival of asymptomatic PML in natalizumab‐treated MS patients
12. Longitudinal Stability of Anti-JC Virus Antibody Status in Multiple Sclerosis Patients: Results of STRATIFY-1 (S30.001)
13. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
14. Evaluation of the Incidence of Anti-JC Virus Antibodies in a Cohort of Natalizumab-Treated Patients
15. PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis
16. Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.